Consistently, co-administration of DS/Cu remarkably reduced tumor burden in the B-ALL PDX models, reflected by significantly less human CD45+ cells in bone marrow (BM, Figure 5B) and spleen (SP, Figure 5C) compared to control mice (P<0.001 for each case). This evidence concerns the gene PTPRC and neoplasm.